Health Condition 1: null- ICU patients
Conditions
Interventions
None listed
Sponsors
KEM Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients admitted in either MICU, PICU or in Hematology ward and receiving antifungal drugs as a part of his/her treatment. 2. Patients or LAR willing to give informed consent
Exclusion criteria
Exclusion criteria: 1. Re-consent refusal from patient, after regaining consciousness when admitted in unconscious state 2. Patients receiving prophylactic antifungal therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a. extent of use of antifungal drugs Prescribed Daily Doses (PDDs) & Duration Of Therapy (DOTs) b. Appropriateness of antifungal useTimepoint: a. extent of use of antifungal drugs Prescribed Daily Doses (PDDs) & Duration Of Therapy (DOTs) b. Appropriateness of antifungal use | — |
Secondary
| Measure | Time frame |
|---|---|
| a. Total number of adverse events occurring in patients receiving antifungal drugs d. Percentage of adverse reactions causally related to AFAs: according to WHO-UMC or Naranjo algorithm c. Severity of ADRs as per modified Hartwig-Siegel scale d. Percentage of ADRs which are preventable, according to Schumock and Thornton scale Timepoint: first visit: Day 0 subsequent visits: daily till participant is discharged | — |
Countries
India
Contacts
Public ContactDr Kruttika Chitnis
KEM Hospital
Outcome results
None listed